Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX.

IF 28.4 1区医学 Q1 Biochemistry, Genetics and Molecular Biology Jama Oncology Pub Date : 2025-01-23 DOI:10.1001/jamaoncol.2024.5917

Thomas F Stoop, Toshitaka Sugawara, Atsushi Oba, Isabel M Feld, Stijn van Roessel, Eran van Veldhuisen, Y H Andrew Wu, Jo Nishino, Mahsoem Ali, Adnan Alseidi, Alain Sauvanet, Antonello Mirabella, Antonio Sa Cunha, Arto Kokkola, Bas Groot Koerkamp, Daniel Pietrasz, Dyre Kleive, Giovanni Butturini, Giuseppe Malleo, Hanneke W M van Laarhoven, Isabella Frigerio, Jeanne Dembinski, Jin He, Johan Gagnière, Jörg Kleeff, Jose M Ramia, Keith J Roberts, Knut J Labori, Marco V Marino, Massimo Falconi, Michael B Mortensen, Mickaël Lesurtel, Morgan Bonds, Nikolaos Chatzizacharias, Oliver Strobel, Olivier Turrini, Oonagh Griffin, Oskar Franklin, Per Pfeiffer, Richard D Schulick, Roberto Salvia, Roeland F de Wilde, Safi Dokmak, Salvador Rodriguez Franco, Simone Augustinus, Stefan K Burgdorf, Stefano Crippa, Thilo Hackert, Timo Tarvainen, William R Burns, Wells Messersmith, Johanna W Wilmink, Richard A Burkhart, Marco Del Chiaro, Marc G Besselink

{"title":"Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX.","authors":"Thomas F Stoop, Toshitaka Sugawara, Atsushi Oba, Isabel M Feld, Stijn van Roessel, Eran van Veldhuisen, Y H Andrew Wu, Jo Nishino, Mahsoem Ali, Adnan Alseidi, Alain Sauvanet, Antonello Mirabella, Antonio Sa Cunha, Arto Kokkola, Bas Groot Koerkamp, Daniel Pietrasz, Dyre Kleive, Giovanni Butturini, Giuseppe Malleo, Hanneke W M van Laarhoven, Isabella Frigerio, Jeanne Dembinski, Jin He, Johan Gagnière, Jörg Kleeff, Jose M Ramia, Keith J Roberts, Knut J Labori, Marco V Marino, Massimo Falconi, Michael B Mortensen, Mickaël Lesurtel, Morgan Bonds, Nikolaos Chatzizacharias, Oliver Strobel, Olivier Turrini, Oonagh Griffin, Oskar Franklin, Per Pfeiffer, Richard D Schulick, Roberto Salvia, Roeland F de Wilde, Safi Dokmak, Salvador Rodriguez Franco, Simone Augustinus, Stefan K Burgdorf, Stefano Crippa, Thilo Hackert, Timo Tarvainen, William R Burns, Wells Messersmith, Johanna W Wilmink, Richard A Burkhart, Marco Del Chiaro, Marc G Besselink","doi":"10.1001/jamaoncol.2024.5917","DOIUrl":null,"url":null,"abstract":"Importance: The effect of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) chemotherapy on overall survival (OS) is unclear because current studies do not account for the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen.Objective: To investigate the association of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX with OS, taking into account the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen.Design, setting, and participants: This retrospective cohort study included patients with localized pancreatic adenocarcinoma treated with 2 to 11 cycles of preoperative (m)FOLFIRINOX followed by resection across 48 centers in 20 countries from 2010 to 2018. Patients who died within 3 months after surgery were excluded (landmark). Data were analyzed from February 1 to December 31, 2023.Exposures: Preoperative (m)FOLFIRINOX chemotherapy followed by resection and eventually followed by adjuvant chemotherapy.Main outcomes and measures: The primary outcome was OS, calculated from the 3-month landmark. Cox regression analysis, including interaction analyses, was performed to investigate the association of adjuvant chemotherapy with OS.Results: Overall, 767 patients were included after resection of pancreatic adenocarcinoma (median [IQR] age, 62 [55-67] years; 404 [52.7%] male). Adjuvant chemotherapy was independently associated with prolonged OS (hazard ratio [HR], 0.66; 95% CI, 0.49-0.87), confirmed by adjusted OS curves. The interaction analysis to assess estimated treatment effect across subgroups was not statistically significant. The forest plot and interaction test suggest that the association of adjuvant chemotherapy was lower among patients receiving 8 or more cycles of preoperative (m)FOLFIRINOX, those who had radiological response, and those with ypN0 disease. Compared to no adjuvant chemotherapy, both adjuvant (m)FOLFIRINOX (HR, 0.57; 95% CI, 0.40-0.80) and other multiagent adjuvant regimens (HR, 0.61; 95% CI, 0.41-0.92) were associated with prolonged OS, whereas single-agent adjuvant chemotherapy was not (HR, 0.75; 95% CI, 0.55-1.03).Conclusions and relevance: In this cohort study, adjuvant (m)FOLFIRINOX and other multiagent chemotherapy regimens were associated with improved OS following resection of localized pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX, whereas single-agent adjuvant chemotherapy was not. The impact of adjuvant chemotherapy on OS may be lower in subgroups such as patients with 8 or more preoperative cycles of (m)FOLFIRINOX, those having radiological response, and those with ypN0.","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jama Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaoncol.2024.5917","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

Importance: The effect of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) chemotherapy on overall survival (OS) is unclear because current studies do not account for the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen.

Objective: To investigate the association of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX with OS, taking into account the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen.

Design, setting, and participants: This retrospective cohort study included patients with localized pancreatic adenocarcinoma treated with 2 to 11 cycles of preoperative (m)FOLFIRINOX followed by resection across 48 centers in 20 countries from 2010 to 2018. Patients who died within 3 months after surgery were excluded (landmark). Data were analyzed from February 1 to December 31, 2023.

Exposures: Preoperative (m)FOLFIRINOX chemotherapy followed by resection and eventually followed by adjuvant chemotherapy.

Main outcomes and measures: The primary outcome was OS, calculated from the 3-month landmark. Cox regression analysis, including interaction analyses, was performed to investigate the association of adjuvant chemotherapy with OS.

Results: Overall, 767 patients were included after resection of pancreatic adenocarcinoma (median [IQR] age, 62 [55-67] years; 404 [52.7%] male). Adjuvant chemotherapy was independently associated with prolonged OS (hazard ratio [HR], 0.66; 95% CI, 0.49-0.87), confirmed by adjusted OS curves. The interaction analysis to assess estimated treatment effect across subgroups was not statistically significant. The forest plot and interaction test suggest that the association of adjuvant chemotherapy was lower among patients receiving 8 or more cycles of preoperative (m)FOLFIRINOX, those who had radiological response, and those with ypN0 disease. Compared to no adjuvant chemotherapy, both adjuvant (m)FOLFIRINOX (HR, 0.57; 95% CI, 0.40-0.80) and other multiagent adjuvant regimens (HR, 0.61; 95% CI, 0.41-0.92) were associated with prolonged OS, whereas single-agent adjuvant chemotherapy was not (HR, 0.75; 95% CI, 0.55-1.03).

Conclusions and relevance: In this cohort study, adjuvant (m)FOLFIRINOX and other multiagent chemotherapy regimens were associated with improved OS following resection of localized pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX, whereas single-agent adjuvant chemotherapy was not. The impact of adjuvant chemotherapy on OS may be lower in subgroups such as patients with 8 or more preoperative cycles of (m)FOLFIRINOX, those having radiological response, and those with ypN0.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Jama Oncology Medicine-Oncology

CiteScore

37.50

自引率

1.80%

发文量

423

期刊介绍： At JAMA Oncology, our primary goal is to contribute to the advancement of oncology research and enhance patient care. As a leading journal in the field, we strive to publish influential original research, opinions, and reviews that push the boundaries of oncology science. Our mission is to serve as the definitive resource for scientists, clinicians, and trainees in oncology globally. Through our innovative and timely scientific and educational content, we aim to provide a comprehensive understanding of cancer pathogenesis and the latest treatment advancements to our readers. We are dedicated to effectively disseminating the findings of significant clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our ultimate objective is to facilitate the translation of new knowledge into tangible clinical benefits for individuals living with and surviving cancer.

期刊最新文献

Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Correction to Open Access. Critical Review on Breast Cancer Research. Critical Review on Breast Cancer Research-Reply. New CMS Illness Navigation Codes: LinchPIN to Ensuring Better Access to Care?